Advanced, non-local delivery oncolytic virus clinical program
Ovarian Cancer Program
-
-
- Preparing for Phase 3 registration trial in platinum-resistant/refractory ovarian cancer (PRROC)
- Met preestablished endpoint of our Phase 2 in PRROC
Systemic Delivery Program
-
-
- Preparing to initiate a Phase 2 trial in recurrent non-small cell lung cancer (NSCLC)
- Promising early clinical trials in solid tumors demonstrate feasibility of systemic administration
Potential utility against broad spectrum of tumor types and metastatic disease
Physician-preferred administration
-
-
- “Off-the-shelf” therapeutic
- Flexible routes of delivery: local, regional or systemic routes
Antitumor activity with demonstrated activity as monotherapy and combination therapy
-
-
- Boosts patient’s own immune system to turn “cold” tumors “hot”
- Sensitizes (re-sensitizes) resistant tumors to chemotherapy (platinum)
Robust pipeline – affords multiple ”shots on goal”
-
-
- Active IND in pancreatic cancer for V2ACT, a novel immuno-oncology modality (initiation of clinical trial not yet scheduled)
- 500+ novel strains generated via proprietary CHOICE™ platform
- Clinical-stage Animal Health program (Phase 1 completed; Phase 2 ready)
Manufacturing
-
-
- Company-controlled GMP manufacturing facility in San Diego
- Proprietary large-scale cGMP manufacturing process